Elephantiasis or Lymphatic filariasis (LF) is a parasitic infection that causes significant morbidity and impacts hundreds of millions of people in 73 countries. Most LF is caused by the nematode Wuchereria bancrofti, but Brugia species cause LF in some areas of Southeast Asia. The global program to eliminate LF uses mass drug administration (MDA) of antifilarial drugs in endemic areas to kill the microfilaria (MF) stage of the parasite that is required for ongoing transmission by mosquitos. Better tools are needed for assessing the success of MDA, because of limitations of available diagnostic tests. MF testing is often not feasible, because it requires collection of blood at night in most endemic areas. Existing antibody and antigen tests remain positive long after effective treatment, and their results do not correlate well with current infectivity. The Brugia Rapid test detects antibodies to BmR1, a Brugia protein that is expressed by MF. These antibodies disappear 2–3 years after effective treatment, and that makes the Brugia Rapid test a useful marker for persistent infection in the few countries with brugian filariasis. We set out to develop a novel antibody test for W. bancrofti infection based on a BmR1 homologue in W. bancrofti.

中文翻译：

---

#56：一种用于诊断和监测班氏班氏菌感染的新型检测方法

象皮病或淋巴丝虫病 (LF) 是一种寄生虫感染，可导致严重的发病率并影响 73 个国家/地区的数亿人。大多数LF是由班氏线虫Wuchereria bancrofti引起的，但Brugia物种在东南亚的一些地区引起 LF。消除 LF 的全球计划在流行地区使用抗丝虫药物的大规模药物管理 (MDA) 来杀死蚊子持续传播所需的寄生虫的微丝蚴 (MF) 阶段。由于可用诊断测试的局限性，需要更好的工具来评估 MDA 的成功。MF 检测通常不可行，因为它需要在大多数流行地区在夜间采集血液。现有的抗体和抗原检测在有效治疗后很长时间内仍保持阳性，并且它们的结果与当前的传染性没有很好的相关性。Brugia Rapid 测试检测 BmR1 的抗体，一种BrugiaMF 表达的蛋白质。这些抗体在有效治疗 2-3 年后消失，这使得布鲁氏丝虫快速检测成为少数布鲁氏丝虫病国家持续感染的有用标志物。我们着手开发一个新的抗体试验W.班氏基于在BMR1同源感染W.班氏。